Chemexpress(688131) 证券之星·2025-03-27 16:36Core Viewpoint - The independent directors of Shanghai Haoyuan Pharmaceutical Co., Ltd. have been evaluated for their independence and found to comply with relevant regulations, ensuring they can perform their duties without external influence [1][2]. Group 1 - The board of directors conducted an assessment of the independence of current independent directors Wang Rui, Huang Yong, Li Yuanyuan, and those whose terms will end in January 2025: Gao Yang, Yuan Bin, and Zhang Xingxian [1]. - The evaluation confirmed that the independent directors do not fall under any disqualifying conditions as per the "Management Measures for Independent Directors of Listed Companies" [1][2]. - Independent directors have adhered to the regulations set forth by the China Securities Regulatory Commission and the Shanghai Stock Exchange, ensuring they dedicate sufficient time and effort to fulfill their responsibilities [1].